๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Harbin
Clinical trial register · China

Clinical Trials in Harbin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Harbin Medical University24 AstraZeneca24 Eli Lilly and Company20 Hoffmann-La Roche16 Bristol-Myers Squibb16
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Harbin

545 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
Eli Lilly and Company
Phase 3
1,400
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Recruiting
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
NCT06990867Acute Ischemic Stroke
Corxel Pharmaceuticals
Phase 2/3
740
Baotou, Beijing, Changchun, Guangzhou, Harbin, Kaili, Linfen, Nanyang
2025-05-15
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
Eli Lilly and Company
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Active, closed
Predicting Long-Term Clinical Outcomes in Chinese Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT06856616Breast Neoplasms
The Third Affiliated Hospital of Harbin Medical University
Observational
6,000
Harbin
2025-05-13
Recruiting
A Study of ZL-1310 in Participants With Selected Solid Tumors
NCT06885281Solid Tumors
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
Beijing, Xiamen, Guangzhou, Harbin, Changsha, Changchun, Shanghai
2025-05-12
Recruiting
A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors
NCT06922357Advanced/Metastatic Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2
120
Harbin, Hangzhou
2025-04-24
Recruiting
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
288
Beijing, Guangzhou, Guiyang, Harbin, Luoyang, Nanyang, Zhuzhou, Baotou
2025-04-24
Recruiting
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ยฑ Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
NCT06821503Advanced Pancreatic Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
72
Beijing, Chongqing, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Shenyang
2025-04-11
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
Hoffmann-La Roche
Phase 3
450
Xiangyang, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jiangmen
2025-04-09
Recruiting
Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial
NCT06883864Atrial Fibrillation (AF), Catheter Ablation, Atrial Functional Mitral Regurgitation
Beijing Anzhen Hospital
Not applicable
146
Hefei, Beijing, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2025-04-08
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences
Phase 3
695
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-04-04
Not yet open
A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors
NCT06906731Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
27
Harbin
2025-04
Active, closed
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
NCT06921486Obesity and Overweight
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 2/3
1,003
Beijing, Changzhou, Chengdu, Guangzhou, Guangzhusi, Guizhou, Hangzhou, Harbin
2025-03-31
Not yet open
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
NCT06885840Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 2
100
Hefei, Lanzhou, Dongguan, Foshan, Guangzhou, Baoding, Harbin, Zhengzhou
2025-03-31
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
Daiichi Sankyo
Phase 3
510
Anyang, Beijing, Changchun, Changzhou, Chengdu, Fuzhou, Harbin, Hefei
2025-03-27
Recruiting
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
NCT06795022Hepatocellular Carcinoma
AstraZeneca
Phase 1/2
304
Chengdu, Guangzhou, Harbin, Shanghai
2025-03-27
Active, closed
Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients
NCT06922045Hemophilia
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 3
40
Hefei, Lanzhou, Guangzhou, Shenzhen, Nanning, Tangshan, Harbin, Zhengzhou
2025-03-26
Recruiting
Qinqiao Yan Shu Granules for the Treatment of Acute Pharyngitis (Exterior Wind-Heat Syndrome) Phase II Clinical Trial
NCT06932328Acute Pharyngitis
Jianmin Pharmaceutical Group Co., LTD.
Phase 2
216
Harbin, Changsha, Changchun, Jinan, Luzhou, Tianjin, Wenzhou
2025-03-26
Recruiting
Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety
NCT07185503Mucormycosis in Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China
Observational
60
Dalian, Harbin, Shenyang, Tianjin
2025-03-25
Recruiting
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
NCT06977893HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University
Phase 3
194
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Nantong, Shanghai, รœrรผmqi
2025-03-24
Active, closed
Ischemic Stroke Nutrition Intervention Study
NCT06817512Ischemic Stroke
Harbin Medical University
Not applicable
190
Harbin, Mudanjiang, Qiqihar
2025-03-23
Recruiting
Application of Remimazolam Combined With Esketamine in Painless Gastroscopy and Colonoscopy in Elderly Patients
NCT07002801Gastrointestinal Disease
Harbin Medical University
Not applicable
280
Harbin
2025-03-14
Active, closed
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
NCT06883630Non-Small Cell Lung Cancer
RemeGen Co., Ltd.
Phase 1
121
Beijing, Foshan, Guangzhou, Jiangmen, Gulin, Nanning, Harbin, Hanyang
2025-03-13
Recruiting
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
NCT06854445Diffuse Large Cell B-lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
55
Wuhu, Xiamen, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou
2025-03-12
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
AstraZeneca
Phase 2
80
Beijing, Chengdu, Harbin, Shanghai, Wuhan, Zhengzhou
2025-03-12
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma
BeOne Medicines
Phase 3
300
Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Xuzhou
2025-03-05
Not yet open
Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke
NCT06861426Acute Ischemic Stroke
Ying Gao
Observational
4,460
Lanzhou, Harbin, Zhengzhou, Nanjing, Xuzhou, Changchun, Jining, Xian
2025-03-01
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
Summit Therapeutics
Phase 3
780
Fuyang, Beijing, Fuzhou, Guangzhou, Nanning, Guiyang, Haikou, Harbin
2025-02-27
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3
726
Beijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou
2025-02-27
Active, closed
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323Small Cell Lung Cancer (SCLC)
Amgen
Phase 2
252
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Taiyuan, Chengdu, Tianjin
2025-02-26
Recruiting
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
NCT06778031HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
54
Harbin, Shanghai
2025-02-26
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
530
Beijing, Chongqing, Fuzhou, Xiamen, Shantou, Harbin, Wuhan, Changsha
2025-02-25
Recruiting
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
NCT06797297Melanoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-02-24
Recruiting
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
NCT06741644Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Recruiting
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
NCT06839105Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
214
Fuzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Nanchang, Changchun
2025-02-21
Active, closed
Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer
NCT06702618Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Bengbu, Jiangmen, Xingtai, Harbin, Luohe, Changsha, Nanjing, Nantong
2025-02-20
Recruiting
Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
NCT06796803Potentially Resectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2/3
398
Harbin, Shanghai
2025-02-20
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou
2025-01-29
Recruiting
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
NCT06754891Inflammatory Bowel Diseases
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
135
Bengbu, Wuwei, Guangzhou, Huizhou, Harbin, Luoyang, Nanyang, Zhengzhou
2025-01-28
Recruiting
A Trial of HRS-2189 in Combination With FluvastatinยฑHRS-6209, or HRS-8080ยฑHRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
NCT06679036Advanced Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2
300
Harbin, Zhengzhou
2025-01-21
Recruiting
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06568939Non-Small Cell Lung Cancer
AbbVie
Phase 2
150
Beijing, Fuzhou, Nanning, Harbin, Zhengzhou, Wuhan, Nanchang, Xi'an
2025-01-20
Recruiting
Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy
NCT06776588Lung Cancer
Beidahuang Industry Group General Hospital
Not applicable
200
Harbin
2025-01-15
Recruiting
Effects of Ketone Esters on Circulating Senescent T Lymphocytes (T Cells) and Inflammation Levels in the Elderly
NCT07087093The Elderly
First Affiliated Hospital of Harbin Medical University
Not applicable
20
Harbin
2025-01-07
Recruiting
A Phase โ…  Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors
NCT07229898Advanced Solid Tumors
Henan Genuine Biotech Co., Ltd.
Phase 1
48
Harbin, Jinan, Shanghai, Xinxiang
2025-01-07
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
Pfizer
Phase 3
1,035
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Harbin, Wuhan
2025-01-06
Recruiting
A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies
NCT06718634Relapsed or Refractory Lymphoid Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Harbin
2025-01-02
Recruiting
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
NCT06783569Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer, Colorectal Cancer
JiaRay Group
Phase 1
94
Harbin, Shenyang
2024-12-31
Recruiting
Remote Anxiety Management for ICS-resistant Asthma Study
NCT06732141Asthma
First Affiliated Hospital of Ningbo University
Not applicable
216
Harbin, Hefei, Jingzhou, Ningbo, Ninghai, Taizhou
2024-12-13
Active, closed
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
AbbVie
Phase 2
185
Beijing, Langfang, Harbin, Wuhan, Hangzhou
2024-12-13
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Changsha, Chengdu, Ganzhou, Guangzhou, Hangzhou, Harbin
2024-12-12
Recruiting
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
NCT06584032Advanced Endometrial Cancer
Hutchmed
Phase 3
412
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha
2024-12-12
Recruiting
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT06625593Advanced Solid Tumor
BeOne Medicines
Phase 1
168
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Nanning, Shijiazhuang, Harbin
2024-12-09
Recruiting
Risk Stratification and MRD-driven Maintenance for MM After ASCT
NCT06697483Multiple Myeloma
Peking University People's Hospital
Not applicable
100
Beijing, Harbin
2024-12-01
Recruiting
Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)
NCT03547232Acute Pancreatitis, Complication, Mortality Rate, Organ Failure, Multiple
Peking Union Medical College Hospital
Phase 4
1,504
Beijing, Guiyang, Baoding, Harbin, Dengzhou, Nanyang, Huaian, Nantong
2024-12-01
Recruiting
Diagnosis, Prognosis, and Mechanisms in Panvascular Disease
NCT07151183Panvascular Diseases, Cardiovascular Diseases
Jinwei Tian
Observational
1,000
Harbin
2024-12-01
Not yet open
Study on Lipid Profile Changes in Plasma and Intestinal Mucosa of Patients With Inflammatory Bowel Disease
NCT06680076Inflammatory Bowel Diseases
First Affiliated Hospital of Harbin Medical University
Observational
90
Harbin
2024-12
Active, closed
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis๏ผšBDLL Chinese Cohort
NCT06649721Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis
Huashan Hospital
Phase 3
120
Hefei, Beijing, Xiamen, Nanning, Liupanshui, Shijiazhuang, Harbin, Jiamusi
2024-11-27
Recruiting
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
NCT06668103Non-Small Cell Lung Cancer With EGFR Mutation
Abbisko Therapeutics Co, Ltd
Phase 2
54
Hefei, Harbin, Wuhan, Changchun, Shanghai
2024-11-25
Recruiting
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
NCT06452706Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
42
Bozhou, Chuzhou, Hefei, Maโ€™anshan, Wuhu, Harbin, Zhengzhou, Wuhan
2024-11-14
Recruiting
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
Abbisko Therapeutics Co, Ltd
Phase 2
202
Guiyang, Shijiazhuang, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2024-11-13
By invitation
Multicenter Prospective Cohort Study of Hypertriglyceridemia Acute Pancreatitis
NCT06976099Acute Pancreatitis (AP), Hypertriglyceridemia Acute Pancreatitis
Peking Union Medical College Hospital
Observational
1,000
Beijing, Guangzhou, Zunyi, Harbin, Changsha, Nanjing, Yangzhou, Dalian
2024-11-13
Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
NCT06566586B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
80
Beijing, Lanzhou, Guangzhou, Guigang, Nanning, Harbin, Anyang, Puyang
2024-11-06
Active, closed
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT06601504Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hutchmed
Phase 2
61
Fuzhou, Guangzhou, Nanning, Wuhan, Harbin, Zhengzhou, Changsha, Nanchang
2024-11-05
Active, closed
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768Non-small Cell Lung Cancer, Lung Cancer
Daiichi Sankyo
Phase 1/2
137
Changchun, Hangzhou, Harbin, Jiamusi, Shanghai, Tiyuan, Zhengzhou
2024-10-30
Recruiting
Rapid dFLC Response Predict CHR in AL Amyloidosis
NCT06627309Systemic AL Amyloidosis
Peking University People's Hospital
Observational
50
Beijing, Harbin, Nanjing, Shenyang, Xi'an
2024-10-26
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
NCT06656390Advanced Cancer, Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2
202
Hefei, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Chengde, Harbin
2024-10-24
Recruiting
QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
NCT06456528Cancer Treatment-Induced Thrombocytopenia
Qilu Pharmaceutical Co., Ltd.
Phase 2/3
235
Harbin, Nanjing
2024-10-22
Active, closed
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
NCT06591520Biliary Tract Cancer
Akeso
Phase 3
682
Harbin, Shanghai
2024-10-20
Recruiting
Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy
NCT06090994Colorectal Cancer
Fudan University
Phase 4
756
Harbin, Changzhou, Nanjing, Yangzhou, Shanghai, Hangzhou, Ningbo
2024-10-18
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
1,000
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Huizhou, Nanchang
2024-10-18
Recruiting
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
NCT06598800Advanced Solid Tumor
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Recruiting
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
NCT06682195TNBC, Triple Negative Breast Cancer
First Affiliated Hospital of Zhejiang University
Phase 2
35
Nanchang, Hangzhou, Harbin, Hefei, Jinhua, Nantong, Shanghai, Shanxi
2024-10-09
Active, closed
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer
NCT06599216Breast Cancer, HR+/HER2- Breast Cancer
Harbin Medical University
Phase 2
30
Harbin
2024-10-08
Recruiting
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473Advanced Solid Tumors
BeOne Medicines
Phase 1
310
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou
2024-10-03
Not yet open
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ยฑ Lenvatinib As First-line Treatment for Advanced ICC
NCT06648525Intrahepatic Cholangiocarcinoma (Icc)
Harbin Medical University
Phase 2
68
Harbin
2024-10
Active, closed
Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer
NCT06464692Colorectal Cancer
AbbVie
Phase 1
31
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou
2024-09-30
Recruiting
Bactiseal Catheter Safety Registry Study
NCT06276543Hydrocephalus
Integra LifeSciences Corporation
Observational
200
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu
2024-09-29
Active, closed
A Study in Patients With Myasthenia Gravis in China
NCT06700616Myasthenia Gravis
AstraZeneca
Observational
1,199
Beijing, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Hebei, Henan
2024-09-26
Recruiting
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
NCT06568094Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
100
Harbin, Shanghai
2024-09-25
Not yet open
A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight
NCT06606483Obesity, Overweight and Obesity
MindRank AI Ltd
Phase 2
300
Hefei, Xuancheng, Zibo, Beijing, Haikou, Shijiazhuang, Harbin, Luoyang
2024-09-23
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Eli Lilly and Company
Phase 1
630
Beijing, Harbin, Shanghai
2024-09-12
Active, closed
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
NCT06487559Hepatocellular Carcinoma (HCC)
AbbVie
Phase 1
3
Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang
2024-09-11
Recruiting
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
NCT06554795Solid Tumor, Adult
DualityBio Inc.
Phase 1/2
360
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Nanning, Harbin, Luoyang
2024-09-03
Not yet open
A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients
NCT06469879Small Cell Lung Cancer Limited Stage
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
358
Hefei, Lanzhou, Nanjing, Tangshan, Harbin, Anyang, Xiangyang, Changsha
2024-09
Active, closed
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
Servier Bio-Innovation LLC
Phase 1/2
48
Beijing, Harbin, Zhengzhou, Shenyang, Jinan, Shanghai, Hangzhou
2024-08-31
Recruiting
Peginterferon ฮฑ-2b Injection for Hydroxyurea Resistant or Intolerant ET
NCT06552429Essential Thrombocythemia
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
27
Beijing, Fujian, Guangzhou, Harbin, Henan, Shanghai, Zhejiang
2024-08-29
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer
Phase 3
444
Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Wuhan, Changsha
2024-08-28
Active, closed
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
NCT06502977Extensive Stage Small Cell Lung Cancer
Amgen
Phase 2
32
Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin
2024-08-27
Recruiting
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
NCT06503783Breast Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Harbin, Shanghai
2024-08-24
Active, closed
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
NCT06610526Chronic Kidney Disease
AstraZeneca
Phase 4
731
Beijing, Changchun, Dongguan, Foshan, Fuyang, Fuzhou, Ganzhou, Harbin
2024-08-23
Recruiting
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
NCT06504732Stomach Neoplasms, Solid Tumor
SUNHO๏ผˆChina๏ผ‰BioPharmaceutical CO., Ltd.
Phase 2/3
574
Harbin, Shenyang
2024-08-15
Recruiting
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
NCT07110883Advanced Solid Tumor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
400
Harbin, Shanghai
2024-08-15
Active, closed
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658Diffuse Large B-Cell Lymphoma
Genmab
Phase 3
379
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2024-08-13
Active, closed
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
NCT06332014Osteoporosis
Amgen
Phase 4
102
Beijing, Chongqing, Guangzhou, Harbin, Huaian, Nanjing, Suzhou, Xuzhou
2024-08-06
Recruiting
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
NCT06496490Non-Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
270
Fuzhou, Foshan, Guangzhou, Jiangmen, Shenzhen, Nanning, Zunyi, Harbin
2024-08-06
Recruiting
Phase 2 Study of WGI-0301 for Advanced HCC
NCT06309485Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd.
Phase 2
60
Shanghai, Changsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan
2024-07-31
Active, closed
SAVE-PCI: NyokAssistโ„ข Small-Bore VAD vs. IABP in Elective High-Risk PCI
NCT07010965High-Risk PCI
magAssist, Inc.
Not applicable
236
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Lanzhou, Shanghai, Taiyuan
2024-07-31
Not yet open
Electroacupuncture Treatment of Behavioral and Psycological Symptoms in Patients With Alzheimer's Disease
NCT06523309BPSD (Behavioral and Psycological Symptoms of Dementia), Alzheimer's Dementia
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Observational
1,000
Beijing, Fuzhou, Harbin
2024-07-30
Recruiting
PulseSelectโ„ข PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Beijing, Fuzhou, Harbin, Kunming, Nanjing, Shanghai, Shenzhen, รœrรผmqi
2024-07-23
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
BeOne Medicines
Phase 1/2
630
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-07-23
Rows per page Showing 201–300 of 545
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/harbin?page=3

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 545 of those studies with a site in Harbin.

How many clinical trials are recruiting in Harbin?

308 of the 545 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 60 have not yet opened recruitment, 171 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.